Management

Søren Tulstrup

President and CEO

Søren Tulstrup has a broad and extensive background as senior executive in the global biopharma industry. Recently, he served as CEO of Vifor Pharma AG (VTX:VIFN), a Glattbrugg, Switzerland-based global pharmaceutical company with a market-leading position within chronic kidney disease, annual sales of approximately USD 1 billion and 2,000 employees. Prior to joining Vifor Pharma, he served as Senior Vice President, Global Franchise Head, MPS at Shire Pharmaceuticals, securing strong market performance of Elaprase (INN: Idursulfase), an enzyme-based treatment of the rare disease Hunter syndrome. Søren has also served as CEO of Santaris Pharma A/S, now part of Roche, a leading clinical stage biopharmaceutical company developing RNA-targeted drugs for various therapeutic areas including cancer and rare genetic diseases. Furthermore, Søren has served in several senior commercial roles within Merck & Co., Inc. and Sandoz Pharma AG (Novartis) and he holds a Master of Science, Economics and Business Administration from Copenhagen Business School. Born 1965.

Shareholding: -
Share rights (max*): 51,389

*The possible entitlement of share rights throough the incentive program LTIP2018 is the potential maximum number. Share right allocation could be lower or zero depending on the share price development.

Emanuel Björne

Vice President, Business Development and Investor Relations

Emanuel joined Hansa Medical in 2007 counting more than 15 years of operational experience from Scandinavian Pharma and Biotech industry (Biolin Scientific, Polypeptide Labs and Hansa Medical) serving as Business Analyst, Analytical Chemist and CEO. Emanuel holds a M.Sc. in Engineering Physics (biophysics core) from Lund University and the University of California at Santa Barbara.

Shareholding: 28,350
Share rights (max*): 20,000

*The possible entitlement of share rights throough the incentive program LTIP2016 is the potential maximum number. Share right allocation could be lower or zero depending on the share price development.

Max Sakajja

Vice President, Corporate Strategy

Max joined Hansa Medical in 2017. He has broad corporate development background and had previously worked with corporate finance at Biovitrum/SOBI in the position of Director Mergers & Acquisitions. Before joining Hansa Medical, Max worked with strategy and business development at Envirotainer as the Global Product and Service Development Manager. Max holds an M.Sc. in Biotechnology from the Royal Institute of Technology.

Shareholding: 3,100
Share rights (max*): 20,201

*The possible entitlement of share rights throough the incentive program LTIP2016 and LTIP2018 is the potential maximum number. Share right allocation could be lower or zero depending on the share price development.

Eva-Maria Joed

Vice President, Chief Financial Officer

Eva-Maria joined Hansa Medical in 2015 and brings long and wide experience within finance to the company. She has held positions both as Chief Accountant and CFO and worked in international companies such as Kemira Kemi AB, Johns Manville AB within the Berkshire Hathaway group and Procordia Food AB. She has also been responsible for implementing new financial systems and policies, and for IT. Eva-Maria holds a Master of Science in Business and Economics from Lund University.

Shareholding: 11,000
Share rights (max*): 20,000

*The possible entitlement of share rights throough the incentive program LTIP2016 is the potential maximum number. Share right allocation could be lower or zero depending on the share price development.

Dr. Christian Kjellman

Senior Vice President, Research and Development

Christian joined Hansa Medical in 2008 after serving at BioInvent AB as Senior Scientist focusing on novel target evaluation and antibody technology. Prior to that, he functioned as Head of Research at the biopharmaceutical development company Cartela AB, mainly focusing on novel drug target evaluation. He has extensive research experience in cell- and molecular biology and as an Assistant Professor in Molecular Genetics at Lund University. Christian holds a M.Sc. in Chemical Biology and a Ph.D. in Tumour Immunology from Lund University.

Shareholding: -
Share rights (max*): 54,084

*The possible entitlement of share rights throough the incentive program LTIP2016 and LTIP2018 is the potential maximum number. Share right allocation could be lower or zero depending on the share price development.

Dr. Lena Winstedt

Vice President, Project Management

Lena carries extensive experience from clinical development of biopharmaceuticals and small molecules. Before joining Hansa Medical in 2011, she served as Clinical Project Manager at BioInvent International AB focusing on Phase I clinical trials for biopharmaceuticals in Europe and in the United States. Prior to that she functioned as International Clinical Project Manager at Genmab A/S and Clinical Research Associate at H. Lundbeck AB. Lena holds an M.Sc. in Molecular Biology from Lund University and the University of Glasgow and a Ph.D. in Microbiology from Lund University.

Shareholding: 5,665
Share rights (max*): 25,000

*The possible entitlement of share rights throough the incentive program LTIP 2016 is the potential maximum number. Share right allocation could be lower or zero depending on the share price development.

Henk Doude van Troostwijk

Vice President, Commercial Operations.

Henk has extensive management experience in sales and marketing in the areas of transplantation and orphan drugs.  Before joining Hansa Medical in 2016, Henk served as General Manager of European Commercial Operations and Emerging Markets at Raptor Pharmaceuticals, an orphan disease focused global biopharma company based in the US. Prior to that, he held the position of Business Unit Director Oncology and Transplantation at Genzyme Europe BV. Henk holds an MBA from Henley Management College at the University of Reading, UK.

Shareholding: -
Share rights (max*): 22,100

*The possible entitlement of share rights throough the incentive program LTIP2016 and LTIP2018 is the potential maximum number. Share right allocation could be lower or zero depending on the share price development.

Karin Aschan

Vice President Regulatory Affairs

Karin joined Hansa in 2016. She has a long experience from working within Regulatory Affairs, initially at AstraZeneca, and has worked on EU and US projects in all clinical trial phases through registration up to marketing phase. Karin has held the position as Head of Regulatory Affairs at Active Biotech and at ClinicalDataCare. She has also been working as an independent regulatory consultant. Karin holds a M.Sc. in Pharmacy from Uppsala University.

Shareholding: -
Share rights (max*): 14,504

*Karin is consultant since 2016. Entitled to LTIP2018 upon employment. The possible entitlement of share rights throough the incentive program LTIP2018 is the potential maximum number. Share right allocation could be lower or zero depending on the share price development.